New details confirm an increased risk of developing intracranial meningiomas after prolonged use of the hormonal product cyproterone acetate. Cyproterone acetate is a synthetic progestogen and potent ...

Prolonged high dose use of the hormone drug cyproterone acetate is associated with an increased risk of developing a brain tumour, finds a study of over 250,000 women in France published by The BMJ ...

Cyproterone products with daily doses of 10 mg or more should be restricted because of a risk of developing meningioma, says the safety committee of the European Medicines Agency. Products containing ...

High doses of a widely-used drug used in the hormonal treatment of conditions such as excessive hair growth, early puberty, prostate cancer, are linked to an increased risk of meningioma — the most ...

Women taking the synthetic progestogen cyproterone acetate were at increased risk for brain tumors, a French study found. The analysis of data on over 250,000 girls and women who filled a prescription ...

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has recommended that the use of cyproterone be restricted as a result of the potential risk of meningioma.

Details concerning the Cyproterone Acetate combination medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, ...

Please provide your email address to receive an email when new articles are posted on . Men with prostate cancer who reported having significant hot flushes during androgen suppression treatment had a ...